hymecromone and Squamous-Cell-Carcinoma-of-Head-and-Neck

hymecromone has been researched along with Squamous-Cell-Carcinoma-of-Head-and-Neck* in 1 studies

Other Studies

1 other study(ies) available for hymecromone and Squamous-Cell-Carcinoma-of-Head-and-Neck

ArticleYear
4-Methylumebelliferone Enhances Radiosensitizing Effects of Radioresistant Oral Squamous Cell Carcinoma Cells via Hyaluronan Synthase 3 Suppression.
    Cells, 2022, Nov-25, Volume: 11, Issue:23

    Radioresistant (RR) cells are poor prognostic factors for tumor recurrence and metastasis after radiotherapy. The hyaluronan (HA) synthesis inhibitor, 4-methylumbelliferone (4-MU), shows anti-tumor and anti-metastatic effects through suppressing HA synthase (HAS) expression in various cancer cells. We previously reported that the administration of 4-MU with X-ray irradiation enhanced radiosensitization. However, an effective sensitizer for radioresistant (RR) cells is yet to be established, and it is unknown whether 4-MU exerts radiosensitizing effects on RR cells. We investigated the radiosensitizing effects of 4-MU in RR cell models. This study revealed that 4-MU enhanced intracellular oxidative stress and suppressed the expression of cluster-of-differentiation (CD)-44 and cancer stem cell (CSC)-like phenotypes. Interestingly, eliminating extracellular HA using HA-degrading enzymes did not cause radiosensitization, whereas HAS3 knockdown using siRNA showed similar effects as 4-MU treatment. These results suggest that 4-MU treatment enhances radiosensitization of RR cells through enhancing oxidative stress and suppressing the CSC-like phenotype. Furthermore, the radiosensitizing mechanisms of 4-MU may involve HAS3 or intracellular HA synthesized by HAS3.

    Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Hyaluronan Synthases; Hymecromone; Mouth Neoplasms; Neoplasm Recurrence, Local; Radiation Tolerance; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck

2022